Table 1: Demographic and clinical findings at baseline in patients with early AMD.

Patient no.Age (yr), sexAcuityFollow-up durationFundus* Macular thicknessfERG§
(microm) (no. of responses at B, 3, 6, 9, 12, 15)

177, F0.815Soft drusen, middle subfield3044(B), 5(3), 5(6), 5(9), 5(12), 5(15)
262, F0.615Soft drusen, middle subfield2726(B), 6(3), 6(6), 6(9), 6(12), 6(15)
361, F0.512Soft drusen, middle subfield2505(B), 6(3), 6(6), 6(9), 6(12)
463, F0.712Soft drusen, central and middle subfield2885(B), 6(3), 6(6), 6(9), 5(12)
575, M0.715Soft drusen, middle subfield2794(B), 5(3), 5(6), 6(9), 6(12), 6(15)
685, M0.812Soft drusen, central and middle subfield2605(B), 5(3), 5(6), 5(9), 5(12), 5(15)
770, M0.715Soft drusen, central subfield2804(B), 4(3), 4(6), 5(9), 5(12), 5(15)
871, M1.012Soft confluent drusen, middle subfield2545(B), 6(3), 6(6), 5(9), 5(12)
973, M1.015Soft drusen, central subfield2944(B), 5(3), 5(6), 6(9), 6(12), 6(15)
1081, F0.56Soft drusen, middle subfield2514(B), 4(3), 4(6)
1173, M0.715Soft drusen, central and middle subfield2751(B), 5(3), 6(6), 6(9), 6(12)
1262, F0.615Soft drusen, middle subfield2976(B), 6(3), 6(6), 6(9), 6(12), 6(15)
1373, M1.015Soft drusen, hyperpigm., middle subfield2214(B), 4(3), 5(6), 5(9), 5(12), 4(15)
1468, M0.815Soft confluent drusen, central and middle subfield2422(B), 4(3), 4(6), 6(9), 6(12), 5(15)
1558, M1.06Soft drusen, middle subfield2801(B), 5(3), 5(6)
1663, M0.815Soft confluent drusen, hypopigm., middle subfield2784(B), 5(3), 5(6), 4(9), 5(12), 5(15)
1764, F1.015Soft drusen and hypopigm., middle subfield2642(B), 6(3), 6(6), 5(9), 6(12), 6(15)
1855, M1.015Soft drusen and hyperpigm., central subfield2955(B), 5(3), 6(6), 6(9), 6(12), 5(15)
1970, F0.715Soft drusen and hyperpigm., middle subfield2372(B), 2(3), 1(6), 3(9), 3(12), 4(15)
2079, M0.415Soft drusen and hyperpigm., middle subfield2551(B), 1(3), 4(6), 6(9), 6(12), 6(15)
2170, M1.012Soft drusen and hyperpigm., central subfield2794(B), 5(3), 5(6), 4(9), 4(12)
2270, M0.715Soft confluent drusen, central subfield2905(B), 5(3), 5(6), 5(9), 5(12), 5(15)
2385, M0.312Soft drusen, middle subfield2551(B), 2(3), 2(6)
2471, F1.015Soft drusen, central and middle subfield2804(B), 5(3), 5(6), 6(9), 5(12), 5(15)
2573, F1.015Soft drusen and hyperpigm., middle subfield2663(B), 5(3), 5(6), 5(9), 5(12), 5(15)
2671, F0.615Soft confluent drusen, hypopigm., central subfield2706(B), 6(3), 5(6), 5(9), 6(12), 5(15)
2761, M0.515Soft confluent drusen, hypopigm., middle subfield2652(B), 6(3), 5(6), 6(9), 6(12), 5(15)
2868, F0.615Soft confluent drusen., central subfield2936(B), 5(3), 5(6), 5(9), 5(12), 5(15)
2956, F0.612Soft confluent drusen, middle subfield2776(B), 6(3), 6(6), 5(9), 6(12)

*Macular appearance with reference to drusen type, confluence, and location; RPE abnormalities type and main location1. Follow-up duration (months). §Number of FERG responses that were above noise level (i.e., S/N ratio ≥ 3) at the different modulation depths of the recording protocol; (6) = S/N ratio ≥ 3 at all modulation depths, (5) = S/N ratio < 3 at the lowest modulation depth, (4) = S/N ratio < 3 at the two lowest modulation depths, etc., B: baseline 3, 6, 9, 12, 15 months of supplementation. Months of follow-up.